Document Detail

Salivary antioxidants and metalloproteinases in juvenile idiopathic arthritis.
MedLine Citation:
PMID:  20062821     Owner:  NLM     Status:  MEDLINE    
Juvenile idiopathic arthritis (JIA) is the most common autoimmune inflammatory disease in children; joint inflammation is the hallmark of the disease. Thirty-five children with JIA were studied, of whom 26 had active disease and 14 were receiving anti-TNF therapy (5 with Infliximab, 9 with Etanercept). Sixteen healthy controls also were studied. Saliva samples were obtained for analysis of anti-oxidant status, metalloproteinases (MMPs) and sialochemistry. The total antioxidant status was significantly higher in the saliva of all JIA patients, whether treated (P = 0.014) or not treated (P = 0.038) with anti-TNF agents. The increase in antioxidant status (TAS) in the saliva of the active patients was nearly two times higher than that of non-active patients (P = 0.01). MMP levels were significantly lower in JIA patients than in controls. MMP-9, MMP-3 and MMP-2 were lower in JIA patients without anti-TNF treatment by 36.7% (P = 0.01), 30.0% (P = 0.0001) and 10.7% (P = 0.0001), respectively. A greater reduction in MMP levels was observed in the group of patients treated with anti-TNF drugs: MMP-9, MMP-3 and MMP-2 were lower than in controls by 51.1% (P = 0.0001), 61.5% (P = 0.0001) and 55.4% (P = 0.0001), respectively. Children with JIA exhibited a significantly higher salivary antioxidant activity and significantly lower MMP levels. Anti-TNF treatment was associated with a further decrease in MMP levels in the saliva of JIA patients while an active state of JIA was associated with a further increase in the salivary antioxidant activity. Anti-TNF treatment may modulate the degradation process during the course of arthritis by inhibition of the activity of MMP.
Riva Brik; Irit Rosen; Dana Savulescu; Iris Borovoi; Moshe Gavish; Rafael Nagler
Publication Detail:
Type:  Journal Article     Date:  2009-12-28
Journal Detail:
Title:  Molecular medicine (Cambridge, Mass.)     Volume:  16     ISSN:  1528-3658     ISO Abbreviation:  Mol. Med.     Publication Date:  2010 Mar 
Date Detail:
Created Date:  2010-03-04     Completed Date:  2010-06-01     Revised Date:  2013-05-31    
Medline Journal Info:
Nlm Unique ID:  9501023     Medline TA:  Mol Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  122-8     Citation Subset:  IM    
Meyer Children's Hospital, Haifa, Israel.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antioxidants / analysis*,  metabolism
Arthritis, Juvenile Rheumatoid / drug therapy,  enzymology,  metabolism*
Case-Control Studies
Metalloproteases / analysis*
Oxidants / metabolism
Oxidative Stress
Saliva / chemistry*
Sensitivity and Specificity
Statistics, Nonparametric
Tumor Necrosis Factor-alpha / antagonists & inhibitors
Reg. No./Substance:
0/Antioxidants; 0/Oxidants; 0/Tumor Necrosis Factor-alpha; EC 3.4.-/Metalloproteases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A new view of carcinogenesis and an alternative approach to cancer therapy.
Next Document:  Quantitative histological validation of diffusion MRI fiber orientation distributions in the rat bra...